Injury Recovery & Tissue Repair
BPC-157 and TB-500 FDA Status
Neither substance was nominated to FDA for tissue repair
BPC-157 and TB-500 are sold into sports medicine and orthopedic settings for tendon, ligament and post-surgical recovery. That is not what FDA was asked to evaluate. Its briefing documents, prepared for the advisory committee meeting of 23 July 2026, record the nominated use for TB-500 as wound healing, and for BPC-157 as ulcerative colitis. We checked the record on 30 August 2026. The gap between what was nominated and what is marketed decides more here than any supplier will volunteer.
Neither BPC-157 nor TB-500 appears on the 503A Bulks List at 21 CFR 216.23, the 503B Bulk Drug Substances List, or the list of withdrawn substances at 21 CFR 216.24. Neither is currently listed in Category 1, 2 or 3 of FDA’s 503A nominations document (updated 14 May 2026) or its separate 503B nominations document (updated 21 March 2025). That is not the whole history: FDA’s safety-risks page lists both under “bulk drug substances nominated but withdrawn”, stating that these were “previously in category 2 of the interim policies” and “withdrawn by the nominators.” On the federal sources reviewed on august 2026 we did not identify a 503A or 503B basis permitting compounding of either substance from bulk under the circumstances reviewed here.
Both were reviewed by the Pharmacy Compounding Advisory Committee (PCAC) on 23 July 2026. FDA’s briefing document for each proposed against inclusion. The meeting was advisory and did not itself amend either list, and no rulemaking has followed.
This page provides regulatory tracking and compliance analysis only, not medical or legal advice.
Why the nominated use matters here more than elsewhere. For the July 2026 review, FDA identified the specific use it was evaluating for each substance. For TB-500 that was wound healing by subcutaneous or intramuscular injection. For BPC-157 it was ulcerative colitis. Tendon repair, ligament injury, post-operative recovery and sports injury were not the questions in front of the agency. A supplier quoting the July 2026 proceedings at you is quoting a review of something else.
Scope. This page addresses federal requirements under the Federal Food, Drug, and Cosmetic Act. State pharmacy law, medical practice acts and prescribing rules apply on top. For the framework this rests on, see how the compounding rules work.
HOW WE SUPPORT CLINICS
Phoenix Meds Regulatory Support Model
Tissue repair sourcing turns on a gap most suppliers never raise: the use FDA reviewed and the use being sold to you are not the same. Our support in this category is built around closing that gap before an order, not after one.
Nominated Use Checked Against Yours
We read what the nomination actually asked for and put it beside what the supplier is selling. For both substances on this page those are different things, and the difference is quotable from FDA’s own documents.
Fragment or Whole Molecule
TB-500 is a seven-residue peptide corresponding to residues 17 to 23 of thymosin beta-4; it is not the full-length protein. Literature cited for one is routinely cited for the other. We check which substance a study actually used before it goes in a file.
Both Nominations Documents
FDA publishes separate nomination category documents for sections 503A and 503B, with different contents. We check both. Neither substance here appears in either, and that absence is a finding worth having in writing.
Prescribing Discretion Separated From Sourcing
Broad discretion to prescribe an approved drug off-label is real. It is a different question from what a pharmacy may lawfully compound. In this category the two get treated as one more often than anywhere else on the site.
Pharmacy Partner Checks
For substances with an identified basis, we run credential and documentation checks on pharmacy partners — state-licensed 503A pharmacies and FDA-registered 503B outsourcing facilities operating under CGMP requirements. Facility registration is not product-specific eligibility, and we check the product separately.
Monitoring
We track both Bulks Lists, both nominations documents, FDA’s safety-risks page, warning letters and Federal Register notices, and re-date this page when something moves.
Regulatory Support Delivered
Clinic Benefits
The work is the same whichever way a finding lands. Knowing what FDA was actually asked is as useful as knowing what it decided.
✓ The Nomination Gap Documented
What each substance was nominated for, quoted from FDA’s briefing document, beside what your supplier is selling it for.
✓ Both Documents Checked
503A and 503B nomination categories are separate documents with different contents. We check both and record the result, including absence.
✓ Fragment Confusion Resolved
Which studies used TB-500 and which used full-length thymosin beta-4, so your file does not rest on the wrong molecule.
✓ Supplier Claims Tested
Where a supplier asserts a statutory basis, we compare that against the primary record and tell you whether it holds.
✓ Documentation Support
Where a clinic is assembling a file for its own counsel, we help put together what the FDA record shows, with dates.
✓ Counsel-Ready Sources
The primary documents assembled and linked, so your attorney reads FDA rather than our summary of FDA.
Tissue Repair & Recovery in Clinical Practice
Tissue repair practitioners work in a distinct domain: the goal is structural recovery from acute injury or post-operative trauma rather than cosmetic optimization. This shapes the evidence framework, the protocol timelines (typically acute, weeks to months), and the outcome metrics clinics use to assess functional recovery and tissue integrity.
Licensed providers in sports medicine, orthopedic surgery, and post-operative care have explored peptide-based approaches based on preclinical research suggesting activity in collagen synthesis, angiogenesis, and extracellular matrix remodeling. These explorations remain within the domain of prescriber discretion and clinical judgment, with the understanding that the human clinical evidence for tissue repair remains limited and the regulatory pathway is still undefined.
The Two Peptides in This Category
Each checked independently on August 2026 against 21 CFR 216.23, 21 CFR 216.24, the 503B Bulk Drug Substances List, both FDA nominations documents, FDA’s safety-risks page and the July 2026 briefing documents. Nothing below is carried over from the other substance.
TB-500 (Thymosin Beta-4 Fragment)
What it is: a seven-residue peptide, LKKTETQ, corresponding to residues 17 to 23 of thymosin beta-4. Not the full-length protein, and FDA evaluates the two separately.
What FDA was asked about: wound healing, by subcutaneous or intramuscular injection at 3 mg/mL. Not tendon or ligament repair.
What FDA found. The briefing document is blunt on the human evidence: “The nomination did not include, and FDA did not find any information in the medical literature where TB-500 was administered to patients to treat any disease or condition.” It also records that the substance is not well characterised, and that injectable routes may pose a significant immunogenicity risk.
FDA’s proposal, verbatim: “Accordingly, we propose not adding TB-500 (free base) or TB-500 acetate to the 503A Bulks List.” The 23 July 2026 committee recommendation is advisory and did not amend the list. No rulemaking has followed.
One thing to check in any study: papers cited for TB-500 frequently tested full-length thymosin beta-4. See our comparison of the two peptides.
BPC-157 (Body Protection Compound)
What it is: a 15-residue peptide from human gastric juice, which FDA describes as a pentadecapeptide fragment of Body Protection Compound. Again a partial sequence, not the whole molecule.
What FDA was asked about: ulcerative colitis, across capsules, injections, nasal sprays, suppositories and transdermal cream. Not tissue repair, not post-surgical recovery.
What FDA found. One small trial in ulcerative colitis — roughly 53 subjects randomised, 46 completing, rectal enemas once daily for two weeks. FDA “did not identify any studies that administered BPC-157 via the oral, SC, nasal, or transdermal ROA in subjects with UC.” It also found the substance not well characterised, with an immunogenicity risk noted for parenteral and nasal routes.
FDA’s proposal: against including either the free base or the acetate on the 503A Bulks List. The 23 July 2026 meeting was advisory and no rulemaking has followed.
BPC-157 also appears in our gut health and inflammation category, where the context matches what FDA actually reviewed.
STATUS SUMMARY
Regulatory Status Compared
Updated August 2026. Every source below changes without notice; please verify before relying on any row.
| Question | BPC-157 | TB-500 |
|---|---|---|
| FDA-approved US drug product | None identified | None identified |
| Applicable USP or NF monograph | None identified | None identified |
| Component of an FDA-approved drug product | None identified | None identified |
| 503A Bulks List (21 CFR 216.23) | Not listed | Not listed |
| 503B Bulk Drug Substances List | Not listed | Not listed |
| 503B Bulks List — statutory route | Not listed | Not listed |
| 21 CFR 216.24 — blocks compounding regardless of the rows above | Not listed | Not listed |
| 503A nominations document (14 May 2026) | Does not appear | Does not appear |
| 503B nominations document (21 Mar 2025) | Does not appear | Does not appear |
| Nominated use FDA evaluated | Ulcerative colitis | Wound healing, SC/IM, 3 mg/mL |
| Human data FDA identified | One trial, 53 subjects, rectal enema, two weeks | None — no record of administration to patients for any condition |
| PCAC 23 July 2026 | Briefing document proposed against inclusion; meeting advisory | Briefing document proposed against inclusion; meeting advisory |
| FDA’s stated concerns | Not well characterized; immunogenicity risk noted for parenteral and nasal routes | Not well characterized; immunogenicity risk noted for injectable routes |
| Our finding | No satisfied statutory condition identified | No satisfied statutory condition identified |
Reading the nomination rows correctly.
Neither substance is currently listed in Category 1, 2 or 3. That should not be read as FDA never having evaluated or categorised either one. FDA’s safety-risks page records both as previously in Category 2, with the nominations subsequently withdrawn by the nominators, and FDA separately took both to the advisory committee in July 2026. Current absence from the category documents is not an adverse placement and it is not a favourable one; it is a different thing from either.
The Current Research Landscape
The preclinical literature on both peptides is genuine and peer-reviewed, covering collagen synthesis, angiogenesis and extracellular matrix remodeling in animal models. That work exists and we are not disputing it.
The human record is a different matter, and FDA’s own briefing documents set it out. For TB-500 the agency found no information in the medical literature of the substance being administered to patients for any condition. For BPC-157 it identified one small trial in ulcerative colitis, 53 subjects, rectal enema, two weeks — a route and an indication that have nothing to do with tissue repair.
A registered trial exists and we could not re-verify its detail today. A Phase 2 study of BPC-157 in acute hamstring strain, NCT07437547, was listed on ClinicalTrials.gov and recruiting when we checked in August 2026. We attempted to re-check the record on 2 September 2026 and could not retrieve it, so the design details, enrollment and current status are not confirmed as of this date. Verify the record directly rather than relying on this summary. What does not change either way: a trial in progress does not alter what a pharmacy may lawfully compound today, and no completed randomised trial supports any tissue repair indication for either peptide.
What follows from that, stated plainly and without inference: safety profiles in humans for tissue repair applications are not established, effective dosing ranges for repair endpoints are not clinically established, and candidate populations, contraindications and outcome measures are not clinically defined. None of the above is a recommendation to use these compounds.
CATEGORY-SPECIFIC RISK
Two Questions Specific to This Category
Prescribing discretion is not sourcing eligibility
Practitioners are used to broad discretion in prescribing approved drugs off-label, and that discretion is real. It does not extend to obtaining a substance for which no compounder has an identified statutory basis. The two questions are commonly, and incorrectly, treated as one.
This category produces the confusion more than any other, because the clinical setting is one where off-label judgement is routine and defensible. Clinical prescribing considerations and pharmacy compounding eligibility are separate questions, and a determination about one does not establish the other. A prescriber entirely within their rights on the clinical question may still be sourcing from a supply chain with no identified basis.
A combination inherits every component's position
Some protocols combine BPC-157 and TB-500 on the reasoning that they act on different parts of the repair process. Whether administered separately or blended, the regulatory analysis runs one bulk substance at a time. FDA does not evaluate a blend under a trade name, and no determination attaches to one.
So combining two substances does not by itself establish a compounding basis for either component. Each substance is checked on its own, then the preparation is checked as a preparation — the prescription, the compounder’s standing, the labelling and the quality requirements all apply to the thing actually being made.
What to Verify Before Any Sourcing Decision
Ask which statutory condition the supplier says is satisfied, under which section, and ask for the document. Establish whether you are dealing with a 503A pharmacy filling a patient-specific prescription or a 503B facility supplying office stock, then ask what makes the particular product eligible under that section — registration answers the first question and not the second. Ask what the material is and who supplied it, and obtain the documentation the applicable pathway requires, including a valid certificate of analysis where one is required. A certificate establishes quality information; it does not by itself establish statutory eligibility.
On research-use material: Research Use Only or Not for Human Use labeling does not by itself determine how FDA treats a product. Under 21 CFR 201.128, intended use is established by the circumstances surrounding an article’s distribution — website content, promotional statements, how the product is described to buyers, and distribution practices, alongside the label. In a warning letter dated 17 June 2026 to a distributor in Brooksville, Florida, FDA concluded that two products were unapproved new drugs on the evidence of the firm’s own marketing, notwithstanding how they were labelled. That letter concerned those products and that firm; the principle it illustrates is general. Phoenix Meds does not treat RUO labeling as a basis for concluding that a product may lawfully be supplied or used.
Answers that should stop the conversation: that the July 2026 committee vote authorizes compounding; that removal from a list means clearance; that a 503B registration number settles product eligibility; that a certificate of analysis establishes a statutory basis; or that a study on thymosin beta-4 is a study on TB-500.
Availability Through Phoenix Meds
For BPC-157 and TB-500, singly or combined, we did not identify a satisfied statutory condition under section 503A or section 503B. Because no lawful pathway currently exists for either compound, Phoenix Meds does not arrange or coordinate pharmacy procurement for them. We coordinate sourcing exclusively for substances that satisfy statutory criteria. For these two peptides, our support is limited strictly to regulatory tracking, nomination documentation, and compliance file preparation for your legal counsel.
Our approach in this category is strictly informational. While we coordinate sourcing through licensed pharmacy partners for substances that possess an established statutory basis, we do not coordinate procurement for BPC-157 or TB-500. For these peptides, we test supplier claims against the primary record and assemble the compliance documentation necessary for your legal counsel to assess risk.
Suppliers in this category quote the July 2026 proceedings freely. If one has quoted them to you as though they authorise something, or offered TB-500 on the strength of thymosin beta-4 research, that is worth knowing before you order rather than after.
If FDA opens a rulemaking, amends either Bulks List, or alters either nominations document in a way that affects these substances, we update this page and re-date it.
Verify This Yourself
The regulatory and factual statements above are based on these public FDA sources (checked as on August 2026)
FDA briefing document — BPC-157 — the nominated use, the single human trial identified, the characterisation and immunogenicity findings, and FDA’s proposal. Prepared for the 23 July 2026 meeting.
FDA briefing document — TB-500 — the nominated use quoted on this page, the finding that no administration to patients was identified, and FDA’s proposal in its own words.
21 CFR 216.23 — the 503A Bulks List as codified, plus the paragraph naming substances that may not be used. Neither peptide appears in either.
21 CFR 216.24 — drug products withdrawn or removed for safety or effectiveness reasons. Neither peptide appears.
FDA — 503B Bulk Drug Substances List — the substances outsourcing facilities may use. Neither peptide appears.
FDA — bulk drug substances nominated under section 503A — the 503A categories document, updated 14 May 2026. Neither peptide appears in Category 1, 2 or 3.
FDA — certain bulk drug substances that may present significant safety risks — carries the separate list of substances “nominated but withdrawn”, which includes BPC-157 and Thymosin beta-4 fragment (LKKTETQ), also known as TB-500. Content current 22 April 2026 when checked.
FDA — bulk drug substances nominated under section 503B — the separate 503B categories document, updated 21 March 2025. Neither peptide appears.
FDA — PCAC meeting, 23–24 July 2026 — agenda, roster, questions and both days’ presentations. FDA has published no minutes, transcript or vote record.
21 CFR 201.128 — how intended use is established from the circumstances surrounding distribution.
ClinicalTrials.gov — NCT07437547 — the BPC-157 hamstring strain study. We could not retrieve this record on 2 September 2026; check it directly.
Related Clinic Resources
FDA Regulatory Status & Compounding Considerations
The statutory framework behind every page on this site, with 503A and 503B kept separate.
BPC-157 vs TB-500 for Clinics
The two substances compared, including what each nomination actually asked for.
Gut Health & Inflammation
BPC-157 in the context of the indication it was actually nominated for, alongside KPV.
Skin, Hair & Aesthetic
GHK-Cu by route, and why a blend’s trade name carries no FDA determination.
Immune Support & Healthy Aging
Thymosin Alpha-1 and Epitalon, and why foreign approval reaches neither.
Storage and Handling of Lyophilized Peptides
Maintaining integrity from arrival through reconstitution.
Medical Supply Chain
How the coordination arrangement works end to end, and what documentation sits behind it.
Choosing a Supplier
The questions worth asking, and the answers that should end the conversation.
Disclaimer & Legal Status:
This page is educational and regulatory-tracking information for licensed clinics. It is not medical or legal advice. For current FDA regulatory status, legal compounding authority, and required due diligence, see our complete Legal & Regulatory Status Overview.
Tissue repair protocols operate on narrow safety windows:
Success depends on dosing consistency and the prescriber’s ability to monitor recovery response. The burden of safety monitoring and outcome assessment rests entirely with the prescribing physician. Clinics must establish clear informed consent processes, maintain detailed protocol documentation, and verify supplier credentials independently before initiating any recovery-focused peptide protocol.
Phoenix Meds Inc. operates as a sourcing coordinator only:
We are not physicians, pharmacists, or legal counsel. Nothing on this page constitutes an offer to source these substances. All sourcing decisions must be made by licensed practitioners in consultation with qualified legal counsel.